Summary
A method involving the use of an energy-dispersive X-ray fluorescence spectrometer was developed for assaying total platinum concentrations in body fluids of patients treated with the antitumor drug cis-dichlorodiammineplatinum(II). Sample preparation by this procedure is simple, consisting in adding an internal standard (Zr) to 1 ml of biological fluid or tissue homogenate, pipetting 20 μl of the sample onto a Mylar sample holder, and drying. This produces a thin-film sample, which effectively eliminates absorption enhancement effects due to other elements in the specimen. Standard addition studies were found to be linear in the concentration range of interest (0.1–10.0 μg/ml), with correlation coefficients exceeding 0.99. Minimum detection limits range from 0.10 to 0.25 μg Pt per ml, depending on the body fluid, which is adequate for routine patient monitoring after normal chemotherapeutic doses of cis-dichlorodiammineplatinum(II). In preliminary studies with mammalian liver, standard addition experiments were found to be linear and the minimum detection limit was found to be 1.4 μg/g dry weight.
Similar content being viewed by others
References
Bannister SJ, Sternson LA, Repta AJ, James GW (1977) Measurement of free-circulating cis-dichlorodiammineplatinum (II) in plasma. Clin Chem 23: 2258–2262
Bannister SJ, Sternson LA, Repta AJ (1979) Urine analysis of platinum species derived from cis-dichlorodiammineplatinum(II) by high-performance liquid chromatography following derivatization with sodium diethyldithiocarbonate. J Chromatogr 173: 333–342
Bertin EP (1975) Principles and practice of x-ray spectrometric analysis. 2nd edn. Plenum Press, New York, p 610
Currie LA (1968) Limits for qualitative detection and quantitative determination: application to radiochemistry. Anal Chem 40: 586–593
DeConti RC, Toftness BR, Lange RC, Creasey NA (1973) Clinical and pharmacological studies with cis-diamminedichloroplatinum(II). Cancer Res 33: 1310–1315
Douple EB, Richmond RC (1978) Platinum complexes as radiosensitizers of hypoxic mammalian cells. Br J Cancer 37 [Suppl III]: 98–102
Dritschilo A, Piro AJ, Kelman AD (1979) The effect of cis-platinum on the repair of radiation damage in plateau phase Chinese hamster (V-79) cells. Int J Radiat Oncol Biol Phys 5: 1345–1349
Giauque RD, Goulding FS, Jaklevic JM, Pehl RH (1973) Trace element determination with semiconductor detector x-ray spectrometers. Anal Chem 45: 671–681
Gromley PE, Bull JM, LeRoy AF, Cysyk R (1979) Kinetics of cis-dichlorodiammineplatinum. Clin Pharmacol Ther 25: 351–357
Himmelstein KJ, Patton TF, Belt RJ, Taylor S, Repta AJ, Sternson LA (1981) Clinical kinetics of intact cisplatin and some related species. Clin Pharmacol Ther 29: 658–664
Jones AH (1976) Determination of platinum and palladium in blood and urine by flameless atomic absorption spectrophotometry. Anal Chem 48: 1472–1474
Leh FKV, Wolf W (1976) Platinum complexes: a new class of antineoplastic agents. J Pharm Sci 65: 315–328
LeRoy AF, Wehling ML, Sponseller HL, Friauf WS, Solomon RE, Dedrick RE, Litterst CL, Gram TE, Guarino AM, Beckner DA (1977) Analysis of platinum in biological materials by flameless atomic absorption spectrometry. Biochem Med 18: 184–191
Murthy AK, Russof AH, Anderson KM, Hendrickson FR (1979) Cytotoxicity and influence on radiation dose response curve of cis-diamminedichloroplatinum(II) (cis-DDP). Int J Radiat Oncol Biol Phys 5: 1411–1415
Pera MF Jr, Harder HC (1977) Analysis for platinum in biological material by flameless atomic absorption spectrometry. Clin Chem 23: 1245–1249
Priesner D, Sternson LA, Repta AJ (1981) Analysis of total platinum in tissue samples by flameless atomic absorption spectrophotometry. Elimination of the need of sample digestion. Anal Lett 14 (B15): 1255–1268
Reports (1977) Clinical status of the drug. J Clin Hematol Oncol 7 [two-part]
Rosenberg B, Van Camp L, Krigas T (1965) Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 205: 698–699
Rosenberg B, Van Camp L, Trosko JE, Mansour VH (1969) Platinum compounds: A new class of potent antitumor agents. Nature 222: 385–386
Rozencweig M, von Hoff DD, Slavik M, Muggia FM (1977) Cis-Diamminedichloroplatinum(II): A new anticancer drug. Ann Intern Med 86: 803–812
Stewart DJ, Levens M, Moshe M, Feun L, Luna M, Bonura J, Caprioli RM, Loo TL, Benjamin RS (1982) cis-Diamminedichloroplatinum: chloroplatinum: Human central nervous system distribution and use as a radiosensitizer in malignant brain tumors. Cancer Res 42: 2474–2479
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Seifert, W.E., Stewart, D.J., Benjamin, R.S. et al. Energy-dispersive X-ray fluorescence determination of platinum in plasma, urine, and cerebrospinal fluid of patients administered cis-dichlorodiammineplatinum(II). Cancer Chemother. Pharmacol. 11, 120–123 (1983). https://doi.org/10.1007/BF00254260
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00254260